The World Health Organization announced Monday that it was pausing an ongoing trial of how hydroxychloroquine impacts hospitalized COVID-19 patients over safety concerns of the anti-malaria drug—medicine that President Donald Trump said he was taking for at least two weeks.
A "temporary pause" of the WHO's hydroxychloroquine trial was instituted while "safety data is reviewed," said WHO Director General Tedros Adhanom Ghebreyesus.